PBHHealthcare · Drug Manufacturers - Specialty & GenericThe 7 Wall Street analysts covering Prestige Consumer Healthcare, Inc. hold a median 12-month price target of $70 — +44.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 14 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Prestige Consumer Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Accruals (29): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PBH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +44.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2026 | Canaccord Genuity | Maintains | Buy | $86 → $72 |
| 14 May 2026 | Oppenheimer | Downgrade | Perform | — |
| 7 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 2 Feb 2026 | Jefferies | Maintains | Hold | — |
| 7 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 27 Oct 2025 | Jefferies | Maintains | Hold | — |
| 21 Oct 2025 | Oppenheimer | Maintains | Outperform | — |
| 8 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 21 Mar 2025 | RBC Capital | Maintains | Sector Perform | — |
| 13 Feb 2025 | Oppenheimer | Maintains | Outperform | — |
| 7 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 7 Feb 2025 | DA Davidson | Maintains | Buy | — |
| 11 Nov 2024 | DA Davidson | Maintains | Buy | — |
| 24 Sept 2024 | Jefferies | Assumes | Hold | $70 → $76 |
| 28 Aug 2024 | DA Davidson | Maintains | Buy | — |
| 9 Aug 2024 | Canaccord Genuity | Maintains | Buy | — |
| 9 Aug 2024 | DA Davidson | Maintains | Buy | — |
| 21 June 2024 | DA Davidson | Upgrade | Buy | — |
| 21 May 2024 | Canaccord Genuity | Maintains | Buy | — |
| 16 May 2024 | DA Davidson | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Prestige Consumer Healthcare, Inc. returned −21.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 49% of US stocks
Cheaper than 51% of US stocks
Cheaper than 64% of US stocks
Cheaper than 27% of US stocks
Higher than 43% of US stocks
Higher than 13% of US stocks
Higher than 63% of US stocks
Higher than 80% of US stocks
Higher than 78% of US stocks
Higher than 61% of US stocks
Higher than 74% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Prestige Consumer Healthcare, Inc. has a market value of $2.3B and an enterprise value of $4.3B.
Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter grew 6.5% year on year.
Net income over the same four quarters: $172.0M, a 15.6% net margin.
Diluted earnings per share, trailing twelve months: $3.57.
Free cash flow in the twelve months to 30 June 2026: $235.4M.
Prestige Consumer Healthcare, Inc. spent $121.5M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 13.6×; forward P/E: 9.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Prestige Consumer Healthcare, Inc. employs 890 people — $1.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Prestige Consumer Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Prestige Consumer Healthcare announced it will release its fiscal 2027 second-quarter and first-half earnings results on Thursday, November 5, 2026, before the market opens.
Why it matters — PBH watchers can note the scheduled date and timing of the company's upcoming earnings release.
On October 1, 2026, Prestige Consumer Healthcare, Inc. (PBH) was added to Zacks Investment Research's list of Zacks Rank #1 (Strong Buy) value stocks, alongside BP. The inclusion highlights PBH as a recommended value stock on that date.
Why it matters — PBH watchers would note that the company received a Strong Buy value-stock designation from Zacks, which could draw attention to the stock.
Zacks Investment Research published an analysis comparing Prestige Consumer Healthcare (PBH) and Neogen (NEOG) as potential value options for investors interested in Medical - Products stocks. The piece examines which of the two companies may present itself as the better value choice.
Why it matters — PBH watchers would be interested in how the company's valuation stacks up against a peer in the same sector.
Summer's Eve released survey findings showing that over half of U.S. women have avoided discussing an intimate wellness concern due to embarrassment, despite 63% saying women are more comfortable discussing such topics than five years ago. The survey highlights a gap between broader cultural progress and personal comfort.
Why it matters — A PBH watcher would care because the survey sheds light on ongoing consumer barriers and openness around a category relevant to the company's intimate-care brands.
Zacks Investment Research published a piece comparing Prestige Consumer Healthcare (PBH) and Neogen (NEOG) to determine which of the two Medical - Products stocks is more attractive to value investors. The article is framed as a value-stock comparison between the two companies.
Why it matters — PBH watchers will want to know how the company is being assessed against a peer in the medical-products value-investing space, which could influence how the stock is perceived by value-focused investors.
The 7 Wall Street analysts covering Prestige Consumer Healthcare, Inc. have a median 12-month price target of $70, with estimates ranging from $55 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Prestige Consumer Healthcare, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prestige Consumer Healthcare, Inc. 62 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Prestige Consumer Healthcare, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +44.6% from the last close, and Ticker Nerd's factor model ranks Prestige Consumer Healthcare, Inc. 62 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Prestige Consumer Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $75 over the next 12 months.
Prestige Consumer Healthcare, Inc. returned -21.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Prestige Consumer Healthcare Inc. is a consumer healthcare company that develops, manufactures, markets, distributes, and sells branded over-the-counter health and personal care products.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Prestige Consumer Healthcare to Release Fiscal 2027 Second Quarter Earnings Results". Prestige Consumer Healthcare announced it will release its fiscal 2027 second-quarter and first-half earnings results on Thursday, November 5, 2026, before the market opens.
Prestige Consumer Healthcare Inc. is a consumer healthcare company that develops, manufactures, markets, distributes, and sells branded over-the-counter health and personal care products. Prestige Consumer Healthcare Inc. focuses on everyday self-care categories such as pain relief, sore throat care, eye care, digestive health, skin protection, diaper rash treatment, ear wax removal, women’s care, and oral care. Its portfolio includes well-known products sold through mass merchandisers, drugstores, grocery retailers, dollar stores, convenience channels, club stores, and e-commerce outlets across North America, Australia, and other international markets. The company operates through North American OTC Healthcare and International OTC Healthcare segments, giving it broad exposure to consumer wellness products used for common, recurring health needs. Prestige Consumer Healthcare Inc. plays a specialized role in the market as a branded over-the-counter healthcare provider with a portfolio centered on established consumer brands.
CEO Mr. Ronald M. Lombardi CPA · 890 employees · United States · https://www.prestigebrands.com
